Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011

Eurosurveillance

Volumn , Issue 31, 2014, Pages

  Verhaegen, J ^a   Flamaing, J ^a   De Backer, W ^b   Delaere, B ^c   Van Herck, K ^d,e   Surmont, F ^f   Van Laethem, Y ^g   Van Damme, P ^d   Peetermans, W ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

^f PFIZER INC   (United States)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; TETRACYCLINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BELGIUM; EPSILOMETER TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PHASE CONTRAST MICROSCOPY; PNEUMOCOCCAL INFECTION; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SURVEILLANCE; EMPYEMA; FOLLOW UP; HEART FAILURE; KIDNEY FAILURE; LIVER DISEASE; MENINGITIS; MIDDLE AGED; NEOPLASM; SEASONAL INFLUENZA; SEROLOGY; TREATMENT OUTCOME;

EID: 84906791726     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.es2014.19.31.20869     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention. Update: pneumococcal polysaccharide vaccine usage--United States. MMWR Morb Mortal Wkly Rep. 1984;33(20):273-276, 281.
2. Conseil Supérieur de la Santé. Vaccination antipneumococcique de l'adulte (2013). [Pneumococcal vaccination for adults]. Avis CSS n° 8817. Brussels: Conseil Supérieur de la Santé; 2013. French. Available from: http://www.health.belgium.be/eportal/Aboutus/relatedinstitutions/SuperiorHealthCouncil/publications/factsheetsvaccination/index.htm#.UuorQD2E2Rc
3. Conseil Supérieur de la Santé. Recommandations pour la vaccination des enfants présentant un risque accru de maladie invasive à pneumocoques (MIP). [Vaccine recommendations for children at increased risk of invasive pneumococcal disease]. Avis CSS n° 8757. Brussels: Conseil Supérieur de la Santé; 2013. French. Available from: http://www.health.belgium.be/eportal/Aboutus/relatedinstitutions/SuperiorHealthCouncil/publications/factsheetsvaccination/index.htm#.UuorQD2E2Rc
4. European Medicines Agency. Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) CMHP variation assessment report. London: European Medicines Agency; 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdf
5. Institut Scientifique de Santé Publique (WIV-ISP). 2011 Annual report on pneumococcal surveillance. Brussels: WIV-ISP; 2011. Available from: https://www.wiv-isp.be/epidemio/epifr/plabfr/plabanfr/11_030f_r.pdf
6. Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, Tuerlinckx D, et al. Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges. Vaccine. 2011;29(16):2856-2864. http://dx.doi.org/10.1016/j.vaccine.2011.02.016
7. Vergison A, Tuerlinckx D, Verhaegen J, Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics. 2006;118(3):e801-e809. http://dx.doi.org/10.1542/peds.2005-3195
8. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. Wayne, PA: CLSI; 2012. CSLI document M100-S22.
9. Ardanuy C, Marimon JM, Calatayud L, Gimenez M, Alonso M, Grau I, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One. 2012;7 (8):e43619 http://dx.doi.org/10.1371/journal.pone.0043619
10. Bliss SJ, Larzalere-Hinton F, Lacapa R, Eagle KR, Frizzell F, Parkinson A, et al. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005. Arch Intern Med. 2008;168(7):749-755. http://dx.doi.org/10.1001/archinte.168.7.749
11. Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27(17):2394-2401. http://dx.doi.org/10.1016/j.vaccine.2009.01.127
12. Institut Scientifique de Santé Publique (WIV-ISP). Surveillance des maladies infectieuses chez les enfants en Belgique. PediSurv – Rapport annuel 2010 [Surveillance of infectios diseases in children in Belgium – 2010 annual report]. Brussels: WIV-ISP; 2010. Available from: https://www.wivisp.be/PEDISURV/AnnualReports/2010/jaarverslag_2010_fr.pdf
13. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
14. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3):377-386. http://dx.doi.org/10.1086/431521
15. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17-24. http://dx.doi.org/10.1016/j.jinf.2012.02.017
16. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al.Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-51. http://dx.doi.org/10.1001/jama.294.16.2043
17. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41. http://dx.doi.org/10.1086/648593
18. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746. http://dx.doi.org/10.1056/NEJMoa022823
19. Aguiar SI, Brito MJ, Goncalo-Marques J, Melo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine. 2010;28(32):5167-5173. http://dx.doi.org/10.1016/j.vaccine.2010.06.008
20. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9):1346-1354.http://dx.doi.org/10.1086/521626
21. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760-768. http://dx.doi.org/10.1016/S1473-3099(11)70090-1
22. Mu-oz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-182. http://dx.doi.org/10.1086/524660
23. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792.http://dx.doi.org/10.1001/jama.297.16.1784
24. Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, et al.Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis. 2011;30(12):1511-1519. http://dx.doi.org/10.1007/s10096-011-1251-9
25. Regev-Yochay G, Rahav G, Strahilevitz J, Bishara J, Katzir M, Chowers M, et al.A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7. Vaccine. 2013;31(19):2387-2394. http://dx.doi.org/10.1016/j.vaccine.2013.02.059
26. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012;21(123):57-65. http://dx.doi.org/10.1183/09059180.00008911
27. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49(2):e23-e29.http://dx.doi.org/10.1086/600045
28. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis. 2004;4:21.http://dx.doi.org/10.1186/1471-2334-4-21